Intellia Therapeutics to Present at February Healthcare Investor Conferences

CAMBRIDGE, Mass., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will present or host one-on-one meetings at the following upcoming healthcare conferences in February:

Wednesday, February 14, 2018

Leerink Partners 7th Annual Healthcare Conference

Who: Tom Barnes, Ph.D., Senior Vice President, Innovation Sciences

Location: New York, New York

Presentation Time: 1:00pm EST

Tuesday, February 27, 2018

Credit Suisse 2018 Global Healthcare Conference

Who: Tom Barnes, Ph.D., Senior Vice President, Innovation Sciences

Location: London, United Kingdom

One-on-one meetings only

A live webcast of Intellia’s presentations will be accessible through the Events and Presentations page of the Investor Relations section of the company’s website at www.intelliatx.com. To access the webcasts, please log on to the Intellia website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Intellia’s website for 14 days following each conference.

About Intellia Therapeutics

Intellia Therapeutics is a leading genome editing company focused on the development of proprietary, curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. The combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets

Investor Contact:	Media Contact:
Lindsey Trickett	Jennifer Mound Smoter
Vice President, Investor Relations	Senior Vice President, External Affairs &
+1 857-285-6211	Communications
[email protected]	+1 857-706-1071
	[email protected]

                          

 

Source: Intellia Therapeutics, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• H.C. Wainwright Reiterates Buy Rating on Intellia Therapeutics (NTLA)
• Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 Presented at WCLC 2026
• SURF'S UP FOR THE WORLD'S PAW-SOME-EST COMPETITORS!